ARGX$691.4
$705.09
Chart
Performance
Key Stats
AI ARGX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
Buyargenx SE exhibits strong fundamental performance driven by its innovative biopharmaceutical pipeline and a solid financial position. Thematic tailwinds in autoimmune disease treatment are significant, though recent technical indicators suggest a need for caution regarding short-term price movements. Overall, it presents a compelling long-term investment opportunity.
Thematic
argenx SE is at the forefront of addressing significant unmet needs in autoimmune diseases, benefiting from strong demographic trends and increasing healthcare spending in this segment.
Fundamental
argenx SE demonstrates strong revenue growth and a significant improvement in profitability, supported by a healthy balance sheet with ample cash reserves. The company's transition to profitability is a key positive.
Technical
The stock is exhibiting a generally bullish trend with positive moving average signals, but momentum indicators suggest it might be approaching overbought conditions, indicating potential for short-term consolidation.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 90 |
| Autoimmune Disease Market Growth | 85 |
| Healthcare Spending Trends | 75 |
| Competitive Landscape | 70 |
| Regulatory Environment (Pharma) | 80 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 95 |
| Growth | 90 |
| Balance Sheet Health | 95 |
| Cash Flow | 50 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 50 |
| MACD | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Recent EPS Growth
The company has shown strong earnings performance with EPS estimates beating reported figures in Q2 2025 (+12.73%), Q4 2024 (+4003.93%), and Q3 2024 (+146.14%).
Significant Revenue and Net Income Increase
Revenue has grown significantly from $410.75M in 2022 to $2,190.23M in 2024. Net income has turned positive, reaching $833.04M in 2024, with a net margin of 38.0%, indicating strong revenue-to-profit conversion.
Bearish Points (7)
High Valuation Multiples
The current P/E ratio (TTM: 36.08) and P/S ratio (TTM: 17.2) are relatively high, indicating that the stock may be trading at a premium and could be susceptible to significant price corrections if growth expectations are not met.
Inconsistent Profitability and Negative Margins in Prior Years
While recent periods show positive net income, the company experienced significant net losses in 2021, 2022, and 2023, with substantial negative net margins (-82.1%, -172.8%, -24.1% respectively). This indicates historical volatility in profitability.
Calendar
July 2025
31
Next Earnings Date
H: $3.47
A: $2.61
L: $1.96
H: 824.53M
A: 763.01M
L: 716.09M
Profile
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Seasonals
Price Target
763.94 USD
The 39 analysts offering 1 year price forecasts for ARGX have a max estimate of 1063.11 and a min estimate of 582.44.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in the FcRn inhibitor space with Zilbrysq (rozanolixizumab), challenging Vyvgart in autoimmune indications like Myasthenia Gravis and ITP. Both companies focus on innovative solutions for severe neurological and immunological diseases.
Weight: 93
Developing batoclimab, another investigational FcRn inhibitor, directly competing with Argenx's Vyvgart for various autoimmune indications, making it a key direct rival in the FcRn therapeutic class.
Weight: 88
Active in autoimmune diseases, developing a competing FcRn inhibitor (TAK-755/pezadeptacog alfa) and other plasma-derived therapies, positioning it as a significant competitor and partner in the autoimmune landscape.
Weight: 85
Acquired Alexion Pharmaceuticals, a leader in rare diseases with therapies for complement-mediated disorders and neuromuscular conditions, overlapping with Argenx's therapeutic focus and patient populations.